As per attachment
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals reported standalone revenue of Rs. 3,79,020 lakhs for FY2026, up 1.8% from Rs. 3,72,349 lakhs in FY2025. Profit after tax grew 10.1% to Rs. 1,01,182 lakhs from Rs. 91,906 lakhs. On consolidated basis, revenue was Rs. 3,82,167 lakhs (up 1.9%) and PAT was Rs. 1,03,598 lakhs (up 11.7%). EPS improved to Rs. 59.73 per share from Rs. 54.24. The Board recommended a final dividend of Rs. 57 per share (up from Rs. 54), payable from July 1, 2026 to shareholders on record as of May 29, 2026. The 101st AGM will be held on June 30, 2026. Exceptional items of Rs. 264 lakhs (standalone) arose from sale of surplus residential properties. Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified (clean) opinion on both standalone and consolidated results.
Solid profitability growth with margin expansion despite modest revenue growth indicates operational efficiency gains. Increased dividend signals confidence in financial health and cash generation, which should be positive for shareholder returns.